News Denali Therapeutics Inc.

Stocks

DNLI

US24823R1059

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:22:21 2026-06-11 pm EDT			5-day change	1st Jan Change
20.98 ^USD	+1.80%		+4.62%	+27.62%

Jun. 05	Denali Therapeutics Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 08:45 AM
May. 26	Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says	MT

All News

Mentions Relevance

Jun. 05	Denali Therapeutics Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 08:45 AM
May. 26	Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says	MT
May. 22	Morgan Stanley Cuts Price Target on Denali Therapeutics to $35 From $40, Keeps Overweight Rating	MT
May. 22	Wall Street Packs for the Long Weekend
May. 22	Wedbush Cuts Price Target on Denali Therapeutics to $20 From $23, Keeps Outperform Rating	MT
May. 22	Deutsche Bank Adjusts Denali Therapeutics Price Target to $31 From $35, Maintains Buy Rating	MT
May. 22	Denali, Biogen Discontinue Parkinson's Drug Development Amid Phase 2 Setback; Shares Down Pre-Bell	MT
May. 21	Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study	RE
May. 21	Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease	GL
May. 21	Biogen Inc. and Denali Therapeutics Inc. Provide Update on Phase 2b LUMA Study Of BIIB122 In Early-Stage Parkinson?s Disease	CI
May. 14	Morgan Stanley Trims Price Target on Denali Therapeutics to $40 From $42, Keeps Overweight Rating	MT
May. 12	Denali Therapeutics Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03:00 PM
May. 11	Denali Therapeutics Seeing Encouraging Signals From Avlayah Launch, Oppenheimer Says	MT
May. 08	Wedbush Adjusts Denali Therapeutics Price Target to $23 From $25, Maintains Outperform Rating	MT
May. 07	Denali Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
May. 07	Denali Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 07	Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights	GL
Apr. 21	Wedbush Cuts Price Target on Denali Therapeutics to $25 From $30, Keeps Outperform Rating	MT
Apr. 16	US FDA's accelerated approval for drugs needs more transparency, says research firm	RE
Apr. 06	Denali Therapeutics Regains Full Rights to Dementia Drug Following Takeda Partnership Termination	MT
Apr. 03	Denali Therapeutics Inc. And Takeda Terminate Collaboration Agreement For DNL593	CI
Apr. 03	Takeda Ends Denali Therapeutics Dementia-Drug Partnership	DJ
Apr. 03	Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)	GL
Mar. 26	Deutsche Bank Raises Price Target on Denali Therapeutics to $35 From $26, Keeps Buy Rating	MT
Mar. 26	Morgan Stanley Lifts Price Target on Denali Therapeutics to $42 From $40, Keeps Overweight Rating	MT